Personalized Synergistic Treatment System for Allergic Reactions

Publication ID: 24-11857555_0003_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Personalized Synergistic Treatment System for Allergic Reactions,” Published Technical Disclosure No. 24-11857555_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857555_0003_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,555.

Summary of the Inventive Concept

A novel system integrating hydrocortisone sodium phosphate, monothioglycerol, and cutting-edge technologies like AI, IoT, blockchain, and novel biocompatible materials to provide personalized treatment for allergic reactions.

Background and Problem Solved

The original patent disclosed an aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol, which has limitations in terms of dosage adjustment, treatment monitoring, and data security. The new inventive concept addresses these limitations by incorporating advanced technologies to create a more effective and personalized treatment system.

Detailed Description of the Inventive Concept

The system comprises a wearable device, a mobile application, and an AI-powered algorithm that administers a synergistic combination of hydrocortisone sodium phosphate and monothioglycerol to a subject. The mobile application monitors and adjusts the dosage based on the subject's vital signs and medical history. Additionally, the system can be integrated with IoT-enabled injection devices, blockchain technology, and novel biocompatible materials to enhance its functionality and security. The AI-driven diagnostic tool identifies the optimal dosage and administration route for the combination based on the subject's genetic profile and medical history.

Novelty and Inventive Step

The new claims introduce a synergistic combination of hydrocortisone sodium phosphate, monothioglycerol, and advanced technologies, which provides a non-obvious and novel solution to the problem of personalized treatment for allergic reactions. The integration of AI, IoT, blockchain, and novel biocompatible materials with the pharmaceutical formulation is a significant departure from the original patent and represents a substantial inventive step.

Alternative Embodiments and Variations

Alternative embodiments of the system could include different wearable devices, mobile applications, or AI algorithms. The system could also be adapted for use with other pharmaceutical formulations or treatment regimens. Additionally, the novel biocompatible material could be replaced with other advanced materials to enhance the system's performance.

Potential Commercial Applications and Market

The personalized synergistic treatment system has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of allergy treatment, immunology, and dermatology. The system's ability to provide personalized treatment and real-time monitoring could lead to improved treatment outcomes, increased patient satisfaction, and reduced healthcare costs.

Original Patent Information

Patent NumberUS 11,857,555
TitleAqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol
Assignee(s)Antares Pharma, Inc.